Related Experiment Video
Updated: Jun 17, 2026

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium
Published on: May 31, 2024
[Prognosis in patients having irritable bowel syndrome.]
Abstract:
Irritable bowel syndrome (IBS) is among the most common gastrointestinal disorders. In this survey, the prognosis of patients diagnosed with IBS was examined. In 1982, 81 (2.9%) of the inhabitants in Egilsstaethir health care district had diagnosed IBS on their medical records (ICCH 558). Twelve years later, in 1994, the health records of those patients were examined. Information was gathered through a questionnaire, which 76% answered. Of those who answered 28% had no longer any symptoms, but 38% experienced symptoms once a month or more frequently. The medical records of 11 patients who died were checked, revealing that two had had a confirmed gastrointestinal disease, but not in the colon.
Related Concept Videos
Irritable Bowel Syndrome III: Medical and Nursing Management
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...